Weekly Dengue Prevention Pill Shows Promise in Human Trials
Thailand's Medical Council reports promising results for Mosnodenvir, an oral antiviral taken weekly that protects against all four dengue virus strains. Phase 2 human trials show the drug blocks viral replication early by targeting key viral proteins, offering a potential breakthrough for travelers and outbreak zones where no specific prevention currently exists.
On November 12, 2026, the Medical Council posted an article titled 'Dengue Prevention Drug Mosnodenvir Taken Weekly Shows Good Results in Humans.' Dengue remains a severe and expanding global public health threat, with an estimated 400 million infections and 100 million severe cases annually. Nearly 4 billion people across more than 129 countries are at risk. Recent reports show a severe outbreak in Florida, USA, with 485 cumulative cases this year as of October 24, 2026 — 60 in a single week compared to just 62 all of last year — including one death of an 80-year-old from severe dengue. Currently no antiviral exists specifically for dengue prevention or treatment, creating a major unmet global health need. Research shows Mosnodenvir is an oral small-molecule antiviral effective against all four dengue serotypes. It works by disrupting the interaction between viral proteins NS3 and NS4B, preventing viral replication at the earliest stage. A Phase 2 clinical trial using a controlled human infection model tested daily dosing versus weekly high- and low-dose regimens against placebo. Volunteers started with a loading dose two days before exposure to ensure sufficient blood concentration.
